Repurposing Hetrombopag for Multiple Myeloma by Targeting PNPO: A Celastrol‐Inspired Approach

Read full text Summarise with VIRAT
Authors: Tianyi Yu, Cheng Wang, Jingru Xie, Yongxin Wei, Hongwei Cui, Huaxia Zhang, Fan Zhou, Zhendong Deng, Ya Yang, Chunyan Gu
Cited by: 0
References: 70

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Multiple myeloma (MM) is a malignancy of plasma cells whose excessive immunoglobulin production elevates reactive oxygen species (ROS), promoting pathogenesis. Active compounds from Traditional Chinese Medicine, such as celastrol, can exert antitumour effects by further increasing ROS levels to toxic levels, thereby inducing apoptosis. Our previous study has demonstrated that pyridoxine-5'-phosphate oxidase (PNPO) is the specific target of celastrol. In this study, we discovered that PNPO, a key enzyme involved in vitamin B6 coenzyme metabolism, is highly expressed in various cancers, including MM. Increased PNPO levels correlated with MM disease progression, promoting cell proliferation and inducing osteoclast differentiation via exosomes. Concurrently, through a structure-based virtual screening workflow targeting critical PNPO residues (R95 and K117), we identified Hetrombopag as a potential PNPO inhibitor. Hetrombopag simultaneously inhibited MM cell proliferation and osteoclast differentiation. Preliminary data from clinical trials also supported the idea that hetrombopag treatment can prolong survival in MM patients. Our research highlights the significant role of PNPO in MM progression and suggests hetrombopag as a promising therapeutic option for MM treatment.

Fields of Study & Subjects

Multiple Myeloma Research and Treatments Computational Drug Discovery Methods Natural Compounds in Disease Treatment

Publication details

Journal / source
Basic & Clinical Pharmacology & Toxicology
Volume
138
Issue
5
Pages
e70227–e70227
Publication date
31 March 2026
Language
EN